Akcea Therapeutics Inc
AKCA
AKCA was delisted on the 9th of October, 2020.
74 hedge funds and large institutions have $665M invested in Akcea Therapeutics Inc in 2019 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 35 increasing their positions, 15 reducing their positions, and 4 closing their positions.
300% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 4
133% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 15
35% more call options, than puts
Call options by funds: $16.1M | Put options by funds: $11.9M
19% more funds holding
Funds holding: 62 → 74 (+12)
0.09% more ownership
Funds ownership: 26.17% → 26.26% (+0.09%)
5% less capital invested
Capital invested by funds: $704M → $665M (-$38.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$12.3M |
| 2 |
State Street
Boston,
Massachusetts
|
+$7.34M |
| 3 |
SC
Sculptor Capital
New York
|
+$2.71M |
| 4 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$2.17M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$19.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$9.57M |
| 3 |
BlackRock
New York
|
-$3.65M |
| 4 |
Parallax Volatility Advisers
San Francisco,
California
|
-$825K |
| 5 |
AGA
Altrinsic Global Advisors
Stamford,
Connecticut
|
-$728K |
AKCA Hedge Fund Activity: Q1 2019 in Review
74 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Akcea Therapeutics Inc (AKCA) for Q1 2019, worth a combined $665M — down 5.5% from $704M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new AKCA positions and 4 closed out — a net gain of 12 holders — while 35 added to existing stakes and 15 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $12.3M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $19.3M sold.
- 74 institutional investors held Akcea Therapeutics Inc (AKCA) as of Q1 2019, up from 62 in Q4 2018.
- Funds reported $665M of Akcea Therapeutics Inc stock for Q1 2019, down 5.5% quarter-over-quarter.
- 16 funds opened new Akcea Therapeutics Inc positions in Q1 2019 and 4 closed out, a net change of +12 holders.
- The largest Akcea Therapeutics Inc buyer in Q1 2019 was Citadel Advisors, an estimated $12.3M added.
- The largest Akcea Therapeutics Inc seller in Q1 2019 was EcoR1 Capital, an estimated $19.3M sold.
Based on aggregated 13F filings for Q1 2019.